IP Library › Patent Application 17266122
Patent Application
App. No. 17/266,122

PHARMACEUTICAL SUSPENSION FOR ORAL DOSAGE

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
17/266,122
Abstract

Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Claims (38)

1 . (canceled)

2 . (canceled)

3 . (canceled)

4 . (canceled)

5 . (canceled)

6 . (canceled)

7 . (canceled)

8 . (canceled)

9 . (canceled)

10 . (canceled)

11 . (canceled)

12 . (canceled)

13 . (canceled)

14 . (canceled)

15 . (canceled)

16 . (canceled)

17 . (canceled)

18 . (canceled)

19 . (canceled)

20 . (canceled)

21 . (canceled)

22 . A pharmaceutical composition in the form of a suspension for oral delivery comprising:

(a) aprepitant;

(b) water;

(c) 2 mg/mL to about 3.5 mg/mL xanthan gum as a suspending agent;

(d) a buffering agent in an amount sufficient to make the composition pH about 3.5 to about 7;

(e) wetting agent consisting of a combination of glycerin and poloxamer; and

(f) a binder/filler.

23 . (canceled)

24 . The pharmaceutical composition of claim 22 , wherein the wetting agent comprises 100 mg/mL glycerin.

25 . The pharmaceutical composition of claim 22 , wherein the binder/filler is selected from one or more binders or fillers selected from acacia, agar, alginic acid, carmellose sodium, dextrin, veegum or gel white, gellan gum, sodium alginate, hydroxypropyl starch, maltodextrin, modified starch, pectin, potassium alginate, polyvinyl pyrrolidone, carboxymethyl cellulose or an alkali metal salt thereof, microcrystalline cellulose, bentonite, colloidal silicon dioxide, microcrystalline cellulose/sodium carboxymethylcellulose, and any combination thereof.

26 . The pharmaceutical composition of claim 22 wherein the binder/filler is microcrystalline cellulose/sodium carboxymethylcellulose.

27 . (canceled)

28 . (canceled)

29 . (canceled)

30 . The pharmaceutical composition of claim 22 , wherein the buffering agent is selected from group consisting of citrate, citric acid monohydrate or disodium hydrogen phosphate.

31 . (canceled)

32 - 52 . (canceled)